Thus, therapeutic approaches to halt SAVI disease progression may need to mitigate both the innate immune activity of nonhematopoietic SAVI STING-expressing stroma/parenchymal cells and existing autoimmune lymphocytes for effective treatment of SAVI disease — for example, by sequential or combined BM and lung transplantation. Here, STING1 is linked to STING-associated vasculopathy with onset in infancy.